Novo Nordisk A/S (NYSE:NVO) is Dividend Assets Capital LLC's 4th Largest Position

Dividend Assets Capital LLC boosted its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 24.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 266,187 shares of the company's stock after buying an additional 51,572 shares during the period. Novo Nordisk A/S makes up 3.5% of Dividend Assets Capital LLC's holdings, making the stock its 4th biggest holding. Dividend Assets Capital LLC's holdings in Novo Nordisk A/S were worth $18,484,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Revolve Wealth Partners LLC boosted its position in shares of Novo Nordisk A/S by 8.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company's stock worth $214,000 after purchasing an additional 200 shares in the last quarter. Kestra Private Wealth Services LLC boosted its position in shares of Novo Nordisk A/S by 37.8% during the 4th quarter. Kestra Private Wealth Services LLC now owns 48,640 shares of the company's stock worth $4,184,000 after purchasing an additional 13,331 shares in the last quarter. Activest Wealth Management boosted its position in shares of Novo Nordisk A/S by 1,886.3% during the 4th quarter. Activest Wealth Management now owns 10,766 shares of the company's stock worth $926,000 after purchasing an additional 10,224 shares in the last quarter. Angeles Wealth Management LLC boosted its position in shares of Novo Nordisk A/S by 1.6% during the 4th quarter. Angeles Wealth Management LLC now owns 13,919 shares of the company's stock worth $1,197,000 after purchasing an additional 225 shares in the last quarter. Finally, MFA Wealth Advisors LLC boosted its position in shares of Novo Nordisk A/S by 737.8% during the 4th quarter. MFA Wealth Advisors LLC now owns 6,099 shares of the company's stock worth $525,000 after purchasing an additional 5,371 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company's stock.

Novo Nordisk A/S Stock Down 1.4%

NYSE:NVO traded down $1.15 on Friday, hitting $79.90. The stock had a trading volume of 7,465,072 shares, compared to its average volume of 7,025,617. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. The stock has a market cap of $358.57 billion, a P/E ratio of 24.29, a price-to-earnings-growth ratio of 0.90 and a beta of 0.66. Novo Nordisk A/S has a 1 year low of $57.00 and a 1 year high of $148.15. The firm's fifty day simple moving average is $66.93 and its two-hundred day simple moving average is $80.00.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, meeting the consensus estimate of $0.92. The firm had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. Stifel Nicolaus cut shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. BNP Paribas assumed coverage on shares of Novo Nordisk A/S in a research report on Tuesday, April 15th. They set an "underperform" rating on the stock. BMO Capital Markets reissued a "market perform" rating and set a $64.00 price objective (down previously from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. Wall Street Zen lowered shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Friday, June 6th. Finally, Guggenheim lowered shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a report on Thursday, April 17th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Novo Nordisk A/S presently has an average rating of "Hold" and a consensus price target of $112.00.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.